Kyrgyzstan Medical Device Regulation: EAEU Membership and the Dual-Track Registration Pathway

1. Key takeaways

Kyrgyzstan offers two parallel routes for medical device market access, not one. This follows directly from its status as a full member of the Eurasian Economic Union (EAEU): devices may be registered either under national rules or under the unified Union rules, and both routes remain open in parallel until 2028. The first action for a Chinese manufacturer is therefore not assembling documents but choosing between the two tracks. That choice determines the dossier structure, the testing plan and the order of magnitude of the budget, and every subsequent step of the project is built on it.

2. Legal basis

1. The Treaty on the Eurasian Economic Union, signed on May 29, 2014 — the foundational instrument of the Union legal system, with the Kyrgyz Republic as a participating state.
2. The Agreement on Common Principles and Rules for the Circulation of Medical Devices (medical products and medical equipment) within the Eurasian Economic Union, dated December 23, 2014 — establishing the common principles for device circulation within the Union, with Article 11 providing the transitional arrangements.
3. Law of the Kyrgyz Republic On the Circulation of Medical Devices, No. 216 of December 29, 2023 — the legal foundation of the national track. Article 14 sets out the state registration requirement, and Article 15 provides for the issuance of registration certificates with indefinite validity.
4. Cabinet Resolution No. 513 of August 27, 2024, On Certain Issues of Medical Device Registration, Monitoring of Safety, Quality and Effectiveness, Marking and Packaging Requirements — the procedural instrument of the national track, entering into force 10 days after its official publication.
5. Council of the Eurasian Economic Commission Decision No. 46 of February 12, 2016, Rules for the Registration and Examination of the Safety, Quality and Effectiveness of Medical Devices — the registration and assessment rules of the Union track.
6. The Protocol amending the December 23, 2014 Agreement, signed on December 29, 2025 — extending the transition period.

3. Expert insights

Insight 1: the two tracks have different scopes of effect, and this is the first variable in route selection.

A registration certificate obtained under the national track is valid only within the territory of Kyrgyzstan, whereas a single registration under the Union track produces effects between the reference state and the recognizing states. If a product is destined for Kyrgyzstan alone, the advantage of one registration covering several countries cannot be realized; if the same product is also being introduced into Russia, Kazakhstan and Belarus, the dilution effect of the Union track becomes real. In one sentence: the number of target markets decides whether the Union track is worth it.

Insight 2: the national track does not mean an independent set of national technical requirements.

Article 2 of Cabinet Resolution No. 513 expressly transfers five sets of technical rules — the classification rules, the general safety and effectiveness requirements, the biological effects evaluation, technical testing, and clinical and clinical laboratory trials — to the corresponding decisions of the Eurasian Economic Commission. In other words, what Kyrgyzstan retains is a national procedure, while the technical rules of the Union continue to apply. The belief that the national track allows a manufacturer to bypass Union technical requirements is one of the most common misjudgments in this market, and the typical price of that mistake is a testing plan that has to be rebuilt from scratch.

Insight 3: a deferred window does not mean there is time to wait.

The Protocol of December 29, 2025 moved the deadline for national-track applications from the end of 2025 to December 31, 2027, kept re-registration and registration dossier changes open until December 31, 2028, and correspondingly postponed the starting point for Union-track-exclusive new registrations to January 1, 2028. The purpose of the two-year buffer is to complete migration, not to continue observing. The Protocol is provisionally applied 10 days after signing and enters into force on the date the Eurasian Economic Commission receives the last written notification that a member state has completed its domestic procedures; verified approval progress to date includes approval by the House of Representatives of Belarus on June 3, 2026 and approval by the Russian Federation through Federal Law No. 288-FZ of August 4, 2026, while the domestic ratification status of the Kyrgyz Republic should be confirmed against the currently valid text.

Insight 4: a comparison with neighboring Uzbekistan clarifies the shape of this market.

Uzbekistan is only an observer state of the Union and has no Union track available; a separate national project is mandatory in every case. Kyrgyzstan offers one additional option. Conversely, that additional option also carries an additional layer of decision cost and transition-period risk — after 2028, changes to legacy dossiers will be effectively frozen, and each change will require migration to the Union framework.

4. Practical recommendations

First, decide the market scope before starting technical preparation. We recommend answering one question at the project kickoff meeting: how many Union member states must this product enter within three years? The answer decides the track, the track decides the dossier structure, and the dossier structure decides the testing plan and the budget. Reversing this order causes substantial rework.

Second, treat the national track as a transitional arrangement, not a final one. Obtaining a certificate under the national track in 2027 means that any dossier change after 2029 must be redone under Union rules. For devices that iterate frequently — software-driven products, active equipment, and consumables with frequent formula adjustments — this repeated cost must be built into the whole life-cycle budget of the project.

Third, do not infer Kyrgyzstan market access from a Russian registration certificate. Union membership does not create automatic mutual recognition. A Russian state registration certificate has no effect within Kyrgyzstan, and vice versa — unless the Union track was used and recognition status was obtained in Kyrgyzstan. This is consistent with the conclusions in our delivered Russia and Kazakhstan programs.

Fourth, build a dossier ledger for the transition period. Maintain a ledger organized by registration certificate number, dossier version, change history and re-registration window, and process all change requests for legacy products in a concentrated manner before December 31, 2028, so as to avoid passive migration from 2029 onward.

5. Verification checklist

• □ Confirm the scope of target markets: Kyrgyzstan only, or several Union member states including Russia, Kazakhstan and Belarus;
• □ Confirm the intended pathway: the national track (Law No. 216 plus Cabinet Resolution No. 513) or the Union track (Council Decision No. 46);
• □ Verify the three transition milestones: national-track applications close on December 31, 2027, re-registration and changes close on December 31, 2028, and new registrations follow Union rules only from January 1, 2028;
• □ Confirm whether a currently valid registration document has been obtained in one of the eight reference authorities: the EU, Australia, the United Kingdom, Canada, the United States, Switzerland, Norway or Japan, since this affects the availability of the simplified pathway;
• □ Confirm that an authorized representative who is a resident of Kyrgyzstan has been appointed;
• □ Obtain the latest version of Law No. 216 (current version dated November 3, 2025 in the Ministry of Justice legal database) and the full text of Cabinet Resolution No. 513.

Regulatory information verified as of October 29, 2026.

Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, production site inspection coordination, quality management system conformity support, post-market surveillance and device vigilance system setup, import and distribution compliance, official fee calculation and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations. We maintain a stable local cooperation network in Bishkek, Almaty, Tashkent and Moscow, work in Chinese, Russian and English, and provide executable solutions for the issues foreign manufacturers most often encounter in CIS markets, including authorized representative arrangements, the notarization and legalization chain for powers of attorney, localization of technical documentation, and inspection readiness.

We adhere to one principle: every regulatory conclusion we publish must rest on verifiable official sources. Figures and timelines that cannot be verified are always marked as practical estimates, and experience-based values are never presented as legal requirements.

GRZAN provides registration support in Kyrgyzstan for medical device manufacturers, importers and authorized representatives. For project consultation on Kyrgyzstan or Eurasian Economic Union market access, contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services